Quentin Le Hingrat
Overview
Explore the profile of Quentin Le Hingrat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
2421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Charpentier C, Berzow D, Le Hingrat Q, Kaiser R, Gomes P, Miranda A, et al.
Clin Infect Dis
. 2025 Mar;
PMID: 40071658
Human immunodeficiency virus type 2 (HIV-2) is an attenuated retroviral infection characterized by specific natural susceptibility to antiretroviral drugs and acquired resistance profiles. Based on the latest knowledge of phenotypic...
2.
Alame K, Le Hingrat Q, Catoire P, Chocron R, Eyer X, Hermand C, et al.
J Clin Virol
. 2025 Mar;
177:105775.
PMID: 40068229
Objective: In recent years, there has been increased awareness of the impact of respiratory syncytial virus (RSV) on adult health, especially in elderly patients. Unlike influenza infection, its presentation and...
3.
van Kampen J, van Nood E, Mahmud R, Krullaars Z, Voskamp T, Voskamp M, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofae705.
PMID: 39741997
Background: The treatment management of human immunodeficiency virus (HIV)-2 infection presents greater challenges compared to HIV-1 infection, primarily because of inherent resistance against non-nucleoside reverse transcriptase inhibitors. Integrase strand transfer...
4.
Montrouge T, Bertine M, Peytavin G, Saint Joannis T, Bachelard A, De Truchis P, et al.
Clin Infect Dis
. 2024 Dec;
PMID: 39737782
Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with...
5.
Moisan A, Regue H, Rahou Y, Gaymard A, Oblette A, Avon L, et al.
Clin Microbiol Infect
. 2024 Dec;
PMID: 39725080
No abstract available.
6.
Serris A, Ferre V, Le Hingrat Q, Bachelard A, Charpentier C, Exarchopoulos M, et al.
J Antimicrob Chemother
. 2024 Sep;
79(11):2932-2938.
PMID: 39287977
Introduction: Cabotegravir, an integrase strand transfer inhibitor, and rilpivirine, an NNRTI, constitute the first long-acting (LA), injectable, two-drug ART regimen approved for the maintenance of virological suppression in persons living...
7.
Joly V, Ferre V, Le Hingrat Q, Peytavin G, Cresta M, Charpentier C, et al.
Clin Infect Dis
. 2024 Sep;
PMID: 39283963
This retrospective study evaluated Bictegravir/FTC/TAF in 24 PWHIV, 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load < 40 copies/mL....
8.
de Prost N, Audureau E, Guillon A, Handala L, Preau S, Guigon A, et al.
Ann Intensive Care
. 2024 Jun;
14(1):101.
PMID: 38940865
Background: A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. However,...
9.
Mokrani D, Le Hingrat Q, Thy M, Choquet C, Joly V, Lariven S, et al.
J Infect
. 2024 May;
89(1):106180.
PMID: 38759759
Background: Respiratory syncytial virus (RSV) is widely recognized as a cause of acute respiratory failure in infants and immunocompromised patients. However, RSV can also contribute to acute respiratory failure in...
10.
Konu Y, Takassi E, Peytavin G, Dapam N, Damond F, Oumarou W, et al.
Clin Infect Dis
. 2024 May;
80(1):144-152.
PMID: 38748464
Background: Few data are available on the real-world efficacy of receiving tenofovir-lamivudine-dolutegravir (-DTG) as human immunodeficiencyvirus (HIV) treatment, particularly among young people in West Africa. Here, we evaluated pharmaco-virological outcomes...